PHARMASHOTS NEWSWIRE

Apr 21, 2025 The new technology behind HighField’s immunoliposomes may offer greater safety and efficacy than existing antibody drug conjugates (ADCs) HANGZHOU, China--(BUSINESS WIRE)--HighField Biopharmaceuticals, a clinical stage company using lipid-based therapeutics to treat can

Apr 21, 2025 SEOUL, South Korea, April 21, 2025 /PRNewswire/ -- DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusive licensing agreement with GC Cell, a gene and cell therapy firm, for the

Apr 21, 2025 DESTINY-Breast09 phase 3 trial of Daiichi Sankyo and AstraZeneca’s ENHERTU is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2 positive metastatic patient population versus current first-line standard of care Plans for regulatory s

Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7 Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed1,2,3 UK approval first in the world with submissions under review in 14 mar

Apr 17, 2025 SHANGHAI and BOSTON, April 17, 2025 /PRNewswire/ -- VelaVigo Bio, the U.S. subsidiary of VelaVigo Cayman Limited (VelaVigo), a biotech company with a robust discovery and development platform of multi-specific antibodies and antibody-drug conjugate (ADC), today an

April 18, 2025 Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment